AI Drug-Interaction Checkers Aren’t Clinical Pharmacology: A Safer ED Workflow

At 01:40, a patient with atrial fibrillation, chronic kidney disease, and a long medication list needs treatment for a new infection. A clinician pastes the medications into an AI assistant. The answer returns in seconds. It names several possible interactions, sounds confident, and offers no clear way to tell which warning matters now.

The dangerous question is not whether the tool can name an interaction. It is whether the emergency team can tell a clinically important interaction from a noisy list before the next medication is given. A 2025 comparison of three large language models against established drug-interaction databases found low precision across the models, with major differences in sensitivity and specificity (Comparative evaluation of artificial intelligence platforms and drug interaction screening databases using real-world patient data).

That is not a reason to abandon decision support. It is a reason to put AI in the right place. In the ED, an AI interaction checker can help organize a question or surface a possibility. It should not be the medication reference, the pharmacist, or the final clinical decision.

The first failure is often the medication list

An interaction result is only as good as the list behind it. In the ED, the list may contain an old prescription, a medication the patient stopped, two names for the same drug, a dose that changed last week, or a supplement that never made it into the electronic record. A model can process a perfectly formatted list and still produce a misleading answer if the list does not describe what the patient is taking now.

AHRQ’s medication-reconciliation guidance recommends one shared medication list as the reference point for ordering, screening medications used during care, and preparing the discharge regimen (AHRQ, Developing Change: Designing the Medication Reconciliation Process). That principle should come before any AI step. The team needs a known list, a source for each entry, and a way to mark uncertainty.

The input should include drug, formulation, dose, route, timing when relevant, indication, allergies, organ-function context, pregnancy possibility, and the clinical question. Record whether each item came from the patient, pharmacy, EMS handoff, caregiver, or prior chart. Source and uncertainty change how much confidence the output deserves.

This is also where a prehospital-to-ED handoff can matter. When a medication or dose was given before arrival, the receiving team needs the actual drug, amount, time, and route before an automated check has any chance of being useful. Teams that want to rehearse that handoff can use EMS-MedSim for prehospital-to-ED simulation scenarios. The lesson is simple: do not ask a language model to resolve uncertainty that the care team has not first named.

A language model is not a drug database

A general-purpose language model predicts plausible text. A curated drug-interaction database is built to maintain drug identities, interaction pairs, severity categories, and update processes. Those are different jobs.

The 2025 comparative study illustrates the problem. Against a reference set of 204 clinically relevant interactions across 57 medication lists, ChatGPT, Gemini, and Copilot produced different balances of sensitivity, specificity, and precision. ChatGPT had the highest specificity among the three systems tested, while Gemini had the highest sensitivity; the study reported low precision overall and concluded that the systems did not reach the balance needed for reliable clinical decision-making (the study’s full report). The exact numbers belong to that study population. They should not be treated as a universal ranking of models.

Sort the output before you act

A useful ED workflow separates four questions that AI tools often blend together:

1. Is the medication list trustworthy? If not, reconcile it before interpreting the warning.
2. Is there a plausible interaction? Confirm the pair and the mechanism in an approved reference.
3. Does it matter for this patient now? Consider dose, route, timing, organ function, indication, and the urgency of treatment.
4. What action is safer? Continue, hold, change, monitor, give an antidote, consult pharmacy, or use another treatment.

A high-severity interaction in a database may not be the immediate problem if the patient is not taking the drug, the timing is wrong, or the proposed medication is the only reasonable treatment while a safer monitoring plan is arranged. The opposite is also true: a bland output does not clear a patient whose medication history is incomplete.

Build a stop rule into the workflow. The clinician pauses and asks for pharmacist or senior review when the patient has a narrow-therapeutic-index drug, anticoagulant or antiplatelet therapy, significant kidney or liver dysfunction, a high-risk sedative combination, a serious allergy concern, pregnancy possibility, a time-critical illness, or a medication list that cannot be reconciled. The list is a local governance choice, but the principle is not: higher consequence and higher uncertainty require more human review.

Make the override visible and easy

An ED should not ask clinicians to fight an AI output in silence. The interface and policy should make it clear how to reject a warning, how to request a pharmacist review, and where to record the reason. Useful override reasons include wrong or incomplete medication list, duplicate therapy, irrelevant timing, known tolerated combination, patient-specific benefit, unavailable alternative, or unsupported AI output.

The 2026 All-EM AI Consensus Statement calls for human-centered use in which emergency physicians retain authority for patient-care decisions, physician-led governance, training before deployment, and independent validation with real-world monitoring (ACEP, Leading EM Organizations Issue Consensus Statement on Artificial Intelligence in EM). Those principles fit medication safety: the physician and pharmacist remain accountable for the care decision, while the tool remains something the team evaluates and can override.

NIST’s AI Risk Management Framework gives leaders a useful structure for assigning responsibility, measuring performance, and managing risk across the AI life cycle (NIST AI Risk Management Framework). For a medication tool, that means naming an owner, setting a review interval, tracking version and reference updates, monitoring override patterns, and defining when the tool is paused. A policy that says “use clinical judgment” without a way to observe, support, and escalate that judgment is not a working policy.

Dr. Chet's Take

I have spent more than 25 years watching emergency clinicians make medication decisions with incomplete histories, changing physiology, and a clock that does not stop. The best medication safety tools reduce the work of finding the truth. They do not replace the work of deciding what the truth means for this patient. A confident paragraph from a language model is not a medication consult. It is a prompt to verify.

That being said, I do not want emergency physicians to reject every new tool because some outputs are wrong. I want us to stop pretending that fluency is accuracy. If the list is stale, the model is solving the wrong problem. If the warning is not tied to an approved reference and a patient-specific action, it is noise. The honest answer is that the safest role for a general-purpose model is narrow: organize, summarize, and help a clinician ask a better question while a qualified source answers it.

If you are leading an emergency department, pick one high-consequence medication workflow and test it this month. Name the approved reference, the pharmacist escalation path, the override reasons, and the pause rule. Then run a case with an incomplete medication list. Your team should be able to say what the tool knows, what it does not know, and who makes the final call.

Key Takeaways

• Reconcile the medication list before asking AI to interpret interactions; record the source and uncertainty for each important entry.
• Use general-purpose AI to organize a question, not as the final drug-interaction reference or medication decision-maker.
• Confirm each clinically relevant warning in an approved medication reference and match it to the patient’s dose, timing, organ function, indication, and treatment urgency.
• Define pharmacist or senior-clinician escalation for high-consequence drugs, high uncertainty, and time-critical decisions.
• Make overrides visible, review their patterns, and give the ED authority to pause a tool that creates unsafe noise.

FAQ

Can an AI chatbot safely check drug interactions in the emergency department?

It can support a structured review, but current evidence does not support using general-purpose chatbots as standalone drug-interaction screeners. A 2025 comparison found low precision across the evaluated systems and recommended professional validation against established references (comparative study).

What information should be verified before checking a drug interaction?

Verify the medication name, formulation, dose, route, timing, current use, indication, allergies, and relevant kidney, liver, pregnancy, and treatment details. AHRQ recommends one shared medication list as the reference point for ordering and reconciliation (AHRQ medication-reconciliation guidance).

Who should review an AI-generated interaction warning?

The treating clinician remains responsible for the patient-care decision. Escalate to a pharmacist or senior clinician when the consequence is high, the medication history is uncertain, or the patient needs a time-critical treatment. The All-EM consensus statement supports physician authority, physician-led governance, training, and monitoring for emergency AI use (ACEP consensus statement).

How should an ED measure whether the tool helps?

Track clinically meaningful overrides, confirmed interactions, false-positive warnings, pharmacist escalations, time to medication decision, and cases in which the list was incomplete. Review results by workflow and patient group, and define a pause rule before go-live. NIST’s AI RMF supports ongoing risk management rather than a one-time approval (NIST AI RMF).

If you're an emergency physician (or any clinician treating patients daily) trying to understand how AI will actually impact your clinical practice — not just the hype — I put together a free practical guide. You can download it here: AI in EM Survival Guide.

You can also read AI Drug-Interaction Checkers Aren’t Clinical Pharmacology for a related physician perspective.

Sources

• Comparative evaluation of artificial intelligence platforms and drug interaction screening databases using real-world patient data
• AHRQ: Developing Change — Designing the Medication Reconciliation Process
• FDA: Clinical Decision Support Software
• ACEP: Leading EM Organizations Issue Consensus Statement on Artificial Intelligence in EM
• NIST AI Risk Management Framework
• Related simulation training: EMS-MedSim and EM-Sim
• Books by Dr. Shermer